# OnCo record emerald-3 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/emerald-3/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "emerald-3", "NCT05301842" ;
  schema:name "EMERALD-3"@en ;
  schema:description "In 2026 a dual-immunotherapy regimen plus lenvatinib added to TACE cut the risk of progression by about 30%; whether it extends life is not yet known."@en ;
  schema:url <https://onco.cc/trials/emerald-3/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05301842>, <https://ascopost.com/issues/july-25-2026/emerald-3-shows-benefit-with-stride-plus-tace-in-hepatocellular-carcinoma/> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2022-03-28" ;
  onco:related <https://onco.cc/collections/src-asco-post/> ;
  onco:cancers <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/hcc-intermediate/> ;
  onco:technologies <https://onco.cc/technologies/tace/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/lenvatinib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .